Chuansha, Shanghai, June 29, 2020. — Convalife and Medicilon signed a strategic pact, initiating a long-term cooperation between the two companies.
Based on previous cooperation and the mutual trust, Medicilon and Convalife achieved consensus on the partnership that Medicilon will assist Convalife in new drug development utilizing its integrated pharmaceutical R&D service platform. According to the pact, Convalife will deeply cooperate with Medicilon on multiple projects of their “First-in-Class” or “Best-in-Class” new drug R&D. The cooperation is anticipated to accelerate the process of new drug development and IND filing, to offer better solutions for unsatisfied clinical requirements worldwide.